Physician profile
Benjamin B Freeman
NPI 1912206434
$1,629.57
in general payments reported to CMS, 2019-2025
33 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $99.80 · 2021: $115 · 2023: $133 · 2024: $27.55 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $250.49 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $178.38 | 2019-2025 | Lynparza, Tagrisso |
| Seagen INC. | $174.40 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $166.38 | 2019-2025 | Opdivo |
| Endo Pharmaceuticals INC. | $116.21 | 2023 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $93.10 | 2019-2025 | |
| Eisai INC. | $85.01 | 2019-2023 | |
| Pfizer INC. | $81.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $75.81 | 2019-2025 | |
| Genentech USA, INC. | $56.89 | 2019-2025 | Venclexta |
| Emd Serono, INC. | $48.72 | 2019-2025 | |
| Daiichi Sankyo INC. | $42.75 | 2024-2025 | Injectafer, Datroway |
| Janssen Biotech, INC. | $35.69 | 2025 | Talvey, Darzalex, Rybrevant |
| Lilly USA, LLC | $33.75 | 2019-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $29.54 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $28.23 | 2019 | |
| Incyte Corporation | $25.36 | 2019 | |
| Taiho Oncology, INC. | $23.05 | 2025 | |
| Beone Medicines USA, INC. | $16.38 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $14.70 | 2019 | |
| Tesaro, INC. | $14.30 | 2019 | |
| Foundation Medicine, INC. | $13.88 | 2019 | |
| Eusa Pharma (US) LLC | $13.45 | 2019 | |
| Puma Biotechnology, INC. | $12.04 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.